Martin Shkreli resigns as CEO of Turing Pharmaceuticals after being charged with securities fraud

Controversial Turing Pharmaceuticals CEO Martin Shkreli, who was charged Thursday with securities fraud, has resigned his position and will be replaced, in the interim, by board chairman Ron Tilles.
Martin Shkreli exits federal court in New York, U.S., on Thursday, a day before he resigned as CEO of Turing Pharmaceuticals. He was arrested on alleged securities fraud related to Retrophin Inc., a biotech firm he founded in 2011. (Bloomberg)

Turing Pharmaceuticals CEO Martin Shkreli, who was charged Thursday with securities fraud, has resigned his position.

The company said board chairman Ron Tilles has been named interim CEO.

Shkreli was arrested in New York City and charged with securities fraud related to his former hedge fund and a drug company he once ran.

A seven-count indictment unsealed in Brooklyn Federal Court charged Shkreli with: 

  • Conspiracy to commit securities fraud.
  • Conspiracy to commit wire fraud.
  • Securities fraud. 

He has pleaded not guilty to the charges.

The allegations against Shkreli on Thursday have nothing to do with the price-gouging accusations that turned him into a poster boy for corporate greed back in September. 

Shkreli was widely attacked when he jacked up the price of Daraprim, a potentially life-saving anti-parasitic drug treatment, from $13.50 US a pill to $750.


To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Become a CBC Member

Join the conversation  Create account

Already have an account?